VEGFR-2/DHFR-IN-2 (compound 5b) is a dual inhibitor targeting VEGFR-2 and DHFR, with respective IC50 values of 0.623 μM and 9.085 μM. It demonstrates potent cytotoxicity against C26, HepG2, and MCF7 cancer cell lines, with IC50 values ranging from 3.59 μM to 8.38 μM. VEGFR-2/DHFR-IN-2 holds promise for cancer research [1].

VEGFR-2/DHFR-IN-2, tested across concentrations of 2-1024 μg/mL for 18-72 hours, demonstrates significant antimicrobial activity, evident from minimum inhibitory concentration (MIC) values against various pathogens: Escherichia coli, Pseudomonas aeruginosa, Streptococcus faecalis, Salmonella enterica, Methicillin-Sensitive Staphylococcus aureus (MSSA), Methicillin-Resistant Staphylococcus aureus (MRSA), Candida albicans, and Aspergillus niger at 64, 64, 32, 32, 16, 32, 64, and 256 μg/mL respectively. Additionally, when applied in concentrations ranging from 0.5-100 μM over 48 hours, this compound shows anticancer effects. Furthermore, its inhibition of DHFR and VEGFR-2 is confirmed through tests at 0-100 μM for 30 minutes, with IC50 values of 9.085 μM for DHFR and 0.623 μM for VEGFR-2 inhibition. Cell cytotoxicity assays conducted on C26, HepG2, MCF7, and H69PR cell lines with concentrations of 0.5-100 μM over 48 hours confirm its anticancer activity, exhibiting IC50 values of 3.59, 8.38, 6.75, and 28.45 μM, respectively.